Medtronic wins FDA panel support to expand pacemaker and defibrillator use

Medtronic's ($MDT) push to expand the treatment options for its cardiac resynchronization therapy pacemakers and defibrillators have won the backing of a crucial FDA advisory panel. The Minnesota device giant wants to use its CRT devices for patients who have atrioventricular block and left ventricular systolic dysfunction. The regulatory agency's Circulatory Systems Devices Advisory Panel voted in a close decision Oct. 8 that the overall clinical benefits of biventricular pacing for those indications outweighed any risks. Panelists also backed Medtronic's safety and efficacy arguments by a wide margin. While a panel vote isn't binding, the FDA generally makes its final decision based on its recommendations. Item